Kaihui Nan

Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles

The use of single chemotherapeutic drug has shown some limitations in anti-tumor treatment, such as development of drug resistance, high toxicity and limited regime of clinical uses. The combination of two or more therapeutic drugs is feasible means to overcome the limitations. Co-delivery strategy has been proposed to minimize the amount of each drug and to achieve the synergistic effect for cancer therapies. Attempts have been made to deliver chemotherapeutic drugs simultaneously using drug carriers, such as micelles, liposomes, and inorganic nanoparticles (NPs). Here we reported core-shell NPs that were doubly emulsified from an amphiphilic copolymer methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA). These NPs offered advantages over other nanocarriers, as they were easy to fabricate by improved double emulsion method, biocompatible, and showed high loading efficacy. More importantly, these NPs could co-deliver hydrophilic doxorubicin (DOX) and hydrophobic paclitaxel (TAX). The drug-loaded NPs possessed a better polydispersity, indicating that they are more readily subject to controlled size distribution. Studies on drug release and cellular uptake of the co-delivery system demonstrated that both drugs were effectively taken up by the cells and released simultaneously. Furthermore, the co-delivery nanocarrier suppressed tumor cells growth more efficiently than the delivery of either DOX or TAX at the same concentrations, indicating a synergistic effect. Moreover, the NPs loading drugs with a DOX/TAX concentration ratio of 2:1 showed the highest anti-tumor activity to three different types of tumor cells. This nanocarrier might have important potential in clinical implications for co-delivery of multiple anti-tumor drugs with different properties.

Characterization and biocompatibility of nanohybrid scaffold prepared via in situ crystallization of hydroxyapatite in chitosan matrix.

Hydroxyapatite (HAP) precursor solution was first mixed with an acetic acid chitosan (CS) solution. The mixture was then lyophilized to form the original scaffold, which stored the HAP precursors. The nano HAP crystallized homogeneously from the CS matrix during the alkaline treatment to form a nanohybrid scaffold. Scanning electron microscopy (SEM), X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared spectroscopy (FTIR) were used to investigate the fabrication process of the nanohybrid scaffold. XRD results showed that the in situ deposited mineral (HAP) in the scaffold has phase structure similar to natural bone. FTIR and XPS results indicated that CSs hydroxyl group, amino and amide regulated the nano HAP crystallization process, which resulted in the nano homogeneous distribution of nano HAP and provided nano topographical features for the nanohybrid scaffold. MTT testing and SEM images of human bone mesenchymal stem cells (hBMSCs) cultures revealed the attachment and growth of hBMSCs in the biocomposite scaffold. Cell morphology and viability data showed that the nanohybrid composite scaffold is suitable for use in bioapplications.

Cytotoxicity and biocompatibility evaluation of N,O-carboxymethyl chitosan/oxidized alginate hydrogel for drug delivery application

In this paper, covalently cross-linked hydrogel composed of N,O-carboxymethyl chitosan and oxidized alginate was developed intending for drug delivery application. In vitro/vivo cytocompatibility and biocompatibility of the developed hydrogel were preliminary evaluated. In vitro cytocompatibility test showed that the developed hydrogel exhibited good cytocompatibility against NH3T3 cells after 3-day incubation. According to the results of acute toxicity test, there was no obvious cytotoxicity for major organs during the period of 21-day intraperitoneal administration. Meanwhile, the developed hydrogel did not induce any cutaneous reaction within 72 h of subcutaneous injection followed by slow degradation and adsorption with the time evolution. Moreover, the extraction of developed hydrogel had nearly 0% of hemolysis ratio, which indicated the good hemocompatibility of hydrogel. Based on the above results, it may be concluded that the developed N,O-carboxymethyl chitosan/oxidized alginate hydrogel with non-cytotoxicity and good biocompatibility might suitable for the various drug delivery applications.

Preparation and characterization of nano-hydroxyapatite/chitosan cross-linking composite membrane intended for tissue engineering

In this paper, a series of nano-hydroxyapatite(n-HA)/chitosan cross-linking composite membranes (n-HA; 0, 5, 10, 15, 20 and 30 wt%) were successfully developed by a simple casting/solvent evaporation method. n-HA with size about 20 nm in vertical diameter and about 100 nm in horizontal diameter was successfully synthesized by a hydro-thermal precipitation method, and then dispersed into chitosan/genipin solution with the aid of continuous ultrasound to develop n-HA/chitosan cross-linking composite membranes. The detailed characterizations including Fourier transform infrared spectroscopy (FTIR), X-ray diffractometer (XRD), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), water adsorption and tensile test were performed. With the analysis of FTIR spectra and TGA spectra, it suggested that there was existence of possible interactions between polymer and n-HA. Meanwhile, the n-HA content was greatly effected on the morphology as well as the tensile property of composite membrane. In vitro cytotoxicity test suggested that the developed n-HA/chitosan cross-linking composite membrane was non-cytotoxicity against L929 cells after 24hs incubation might be suitable for further in vivo application.

Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection.

Aim To characterise the pharmacokinetics of triamcinolone acetonide (TA) in various ocular tissues following a single sub-Tenon injection. Methods Twenty-one Chinchilla adult pigmented rabbits received sub-Tenon injection of TA (40 mg in 0.4 ml) in their right eyes. Three animals were killed at each designated time points (3 h, 1 day, 3 days, 7 days, 14 days, 21 days and 30 days) and the globes were snap frozen and dissected into aqueous, iris-ciliary body, vitreous, neuroretina and retinal pigment epithelium (RPE)/choroid. The concentrations of TA in the various ocular tissues were analysed using ultra-performance liquid chromatography, coupled with tandem mass spectrometric detection. Results TA concentration followed a mono-exponential decrease over the study period in all ocular tissues of the injected eyes. The concentration was much higher in the RPE/choroid (892.14±558.11 ng/g at post-injection day 30) than in the other tissues (171.65±136.40 ng/g in neuroretina, 15.65±23.06 ng/ml in vitreous, 3.76±1.79 ng/g in iris-ciliary body, 2.64±0.96 ng/ml in aqueous at post-injection day 30). The TA level in the RPE/choroid had the lowest coefficient of logarithmic regression (0.07 in RPE/choroid, 0.10 in neuroretina, 0.11 in vitreous, 0.17 in iris-ciliary body, 0.18 in aqueous), indicating a 2.6 times slower clearance than in aqueous. The half-life of TA was 10.4 days in RPE/choroid. TA was detectable in the fellow eyes and was also detectable at very low levels in all blood samples during the entire study period. Conclusion TA was mostly cleared from RPE/choroid and retina in a mono-exponential mode. TA was above the therapeutic level for at least 30 days following a sub-Tenon injection.

Electrospun fibrous scaffold of hydroxyapatite/poly (ε-caprolactone) for bone regeneration

Development of fibrous scaffold of hydroxyapatite/biopolymer nanocomposite offers great potential in the field of bone regeneration and tissue engineering. Hydroxyapatite (HA)/poly (ε-caprolactone) (PCL) fibrous scaffolds were successfully prepared by electrospinning dopes containing HA and PCL in this work. It was found that pre-treating HA with γ-glycioxypropyltrimethoxysilane (A-187) was effective in improving HA dispersion both in solutions and in a PCL matrix. Mechanical properties of the scaffolds were greatly enhanced by the filling of A187-HA. The bioactivity of PCL was remarkably improved by the addition of HA and A187-HA. Fibroblasts and osteoblasts were seeded on scaffolds to evaluate the effect of A-187 on biocompatibility of HA/PCL composites. Based on this study, good dispersion of HA in PCL matrix was granted by pretreatment of HA with A-187 and A187-HA/PCL fibrous scaffolds were obtained by electrospinning. These results demonstrated that the scaffolds may possess improved mechanical performance and good bioactivity due to A187-HA incorporation.

A combined chitosan/nano-size hydroxyapatite system for the controlled release of icariin

Icariin, a plant-derived flavonol glycoside, has been proved as an osteoinductive agent for bone regeneration. For this reason, we developed an icariin-loaded chitosan/nano-sized hydroxyapatite (IC–CS/HA) system which controls the release kinetics of icariin to enhance bone repairing. First, by Fourier transform infrared spectroscopy, we found that icariin was stable in the system developed without undergoing any chemical changes. On the other hand, X-ray diffraction, scanning electron microscopy and mechanical test revealed that the introduction of icariin did not remarkably change the phase, morphology, porosity and mechanical strength of the CS/HA composite. Then the hydrolytic degradation and drug release kinetics in vitro were investigated by incubation in phosphate buffered saline solution. The results indicated that the icariin was released in a temporally controlled manner and the release kinetics could be governed by degradation of both chitosan and hydroxyapatite matrix. Finally the in vitro bioactivity assay revealed that the loaded icariin was biologically active as evidenced by stimulation of bone marrow derived stroma cell alkaline phosphatase activity and formation of mineralized nodules. This successful IC–CS/HA system offers a new delivery method of osteoinductive agents and a useful scaffold design for bone regeneration.

Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy

Chemotherapy is among the most common means for clinicians in the fight against various types of tumors. However, severe toxicity with undesirable toxic effects against normal tissues and cells significantly hinders the applications of these chemotherapeutic agents and leads to multiple complications for patients. Recent developments of nanotechnology-enabled drug delivery platforms allow simultaneous delivery of multiple chemotherapeutic agents to target different metabolic pathways of tumor cells, thus providing new opportunities for higher therapeutic efficacy and lower cytotoxicity. Furthermore, multifunctional nanocarriers can also deliver diagnostic agents, including MRI contrast agents and fluorescent probes, to achieve cancer diagnosis and therapy at the same time. This present review discusses the various aspects of current co-delivery strategies and emphasizes the need for novel designs of biocompatible and non or low toxic nanocarriers. Further studies on potential adverse effects of various nanocarriers are warranted.

Preparation and characterization of chitosan nanopores membranes for the transport of drugs

In this paper, a novel chitosan nanopores membrane was developed by selective dissolution of its composition. Polyethylene glycol (PEG) as the porogen was selected to generate the nanopores structure of chitosan membrane. As the observation with scanning electron microscopy (SEM), we could find that the PEG content was greatly influenced on the structure of chitosan membrane. As the PEG content was larger than 50%, the chitosan nanopores membrane could successfully developed. Differential scanning calorimeter (DSC) measurement revealed that the PEG component could not be completely dissolved from the membrane and there was presence the possible interaction (hydrogen bond) between two components. Water adsorption test suggested that the obtained membranes have the great capacity of water adsorption ranging from 162.4 ± 22.5% to 321.5 ± 6.5%. In vitro degradation experiment showed that the obtained chitosan membranes have good biodegradability in the lysozyme solution. The permeability test was performed with two model drugs: vitamin B12 (non-ionic water-soluble drug) and sodium sulfamerazine (ionic water-soluble drug). And the results showed that these two drugs have significant differences in the permeability, indicating that chitosan nanopores membranes can potentially be used to the transport of drugs with controlled diffusion manner.

Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-ε-caprolactone matrix

A subtenon injection of triamcinolone acetonide (TA) is a widely used treatment modality for various chorio-retinal diseases. Although it is less invasive than intravitreal injection, it can produce dose-associated ocular complications and has the disadvantages associated with systemic TA exposure. In this study we have developed and evaluated an episcleral film consisting of TA and poly-ε-caprolactone (PCL). The films were prepared by spraying a mixture of PCL in dichloromethane and TA in acetone. The films were produced as 6mm wide and 12 mm long episcleral plaques. X-ray diffraction demonstrated an even distribution of TA crystals in PCL, although the TA was less crystalized than a native TA control. Fourier transform infrared spectroscopy revealed effective integration of TA within the PCL matrix. An in vitro study of the release of TA from the episcleral plaques showed that TA release rate was only 40-50% that of the equivalent native TA control. An in vivo study demonstrated that the plaques were well tolerated in rabbit eyes with significantly less systemic TA exposure. The episcleral plaques provided therapeutic vitreous TA levels for 3 months, while TA levels in the vitreous were detectable for only 1 month following an equivalent dose by subtenon TA injection. The PCL-TA 30-60 episcleral plaque may be further developed as a better alternative treatment for many chronic vitreo-retinal diseases, providing longer and controlled release and fewer drug-associated complications than those associated with a conventional subtenon injection of TA.